Enveda Raises $311 Million Series E to Push Oral Obesity and Inflammation Drugs Into Later Trials

What happened

Enveda, a biotech that uses artificial intelligence to find medicines in natural chemistry, announced on Sept. 23 that it has raised $311 million in a Series E crossover round. According to BioSpace, Catalio Capital Management led the financing, which brings Enveda’s total fundraising to more than $845 million since its founding.

The company said it will use the money to move its two most advanced candidates, in obesity and eczema, into later-stage development.

Round and company details

• Amount: $311 million Series E crossover round.
• Lead: Catalio Capital Management.
• Other investors: T. Rowe Price Investment Management, Surveyor Capital, Durable Capital Partners, ICONIQ and Lightspeed.
• Total raised: More than $845 million.
• Valuation: Not disclosed in the BioSpace report.

Enveda’s pipeline includes 17 candidates, three of them in human testing:

• ENV-308: An oral candidate for weight loss maintenance that showed tolerability in a Phase 1 trial with a readout in August 2026.
• ENV-294: Reduced eczema severity in an early-stage atopic dermatitis trial, with results posted in July 2026.
• ENV-6946: In development for inflammatory bowel disease.

The company plans to advance ENV-294 and ENV-308 into later-stage trials and new indications, with new studies expected in the coming months, move ENV-6946 through mid-stage development, bring earlier assets into the clinic and expand its PRISM platform. Chief executive Viswa Colluru said “this financing lets us build the company those results deserve.”

Why it matters for the sector

Crossover rounds, in which public-market investors such as mutual funds and hedge funds join venture backers before an IPO, are often seen as a step toward a public listing. The participation of T. Rowe Price, Surveyor, Durable and ICONIQ fits that pattern. BioSpace has reported a steady stream of crossover rounds feeding the 2026 IPO pipeline, which reopened this year after a prolonged slowdown.

The round also highlights continued investor interest in oral treatments for obesity and inflammatory disease. Injectable GLP-1 drugs have transformed obesity care, but developers are looking for oral options and for therapies that help patients maintain weight loss after stopping or reducing injections. In immunology, oral alternatives to injectable biologics for eczema and inflammatory bowel disease are a long-standing goal.

AI drug discovery financing was particularly active in late September. Value Add VC tracked several AI-bio rounds that week, including a $140 million Series C for Basecamp Research led by S32. Large rounds for AI-enabled companies with clinical-stage assets suggest investors are rewarding platforms that have produced candidates in human trials rather than purely computational approaches.

For Enveda, the scale of the raise gives it capacity to fund multiple mid- and late-stage trials at once. Natural-product discovery has historically been slow and labor-intensive, and the company’s pitch is that AI can speed up the identification of active molecules in complex biological mixtures.

The size of a Series E crossover round can also reduce the pressure to go public quickly, allowing a company to choose its timing based on clinical milestones rather than cash needs.

Investors in crossover rounds typically look for clinical proof points that could support a public valuation. For Enveda, the August Phase 1 readout for ENV-308 and the July eczema results for ENV-294 give it early human data in two large markets, and the next set of trials will determine whether those signals hold up in larger patient groups.

Obesity maintenance is a relatively new commercial concept. As more patients reach target weight on GLP-1 medicines, payers and physicians are asking what therapy should follow, which creates an opening for oral options.

What to watch

• The start of later-stage trials for ENV-294 in atopic dermatitis and ENV-308 in weight maintenance.
• Mid-stage data for ENV-6946 in inflammatory bowel disease.
• Any IPO filing, given the crossover investor base.
• Further large financings for AI-enabled drug developers.

Sources: BioSpace, Value Add VC

Why Natural Chemistry Remains a Source of Medicines

Many familiar medicines trace their origins to compounds found in nature. Aspirin’s chemistry is rooted in compounds from willow bark, penicillin was discovered in a mold, and the cancer drug paclitaxel was first isolated from the bark of the Pacific yew. Plants, fungi and microbes produce enormous numbers of chemical compounds, many of them shaped by evolution to interact with biological systems.

The challenge has always been the sheer complexity. A single plant extract can contain thousands of compounds, most present in tiny amounts and many never characterized. Traditional natural-product discovery involved painstaking separation and testing, which helps explain why the approach fell out of favor at many large drugmakers.

Where computation comes in

1. Measurement. Techniques such as mass spectrometry generate detailed data on the molecules present in a sample.
2. Identification. Computational models predict the structures of compounds from those measurements, including compounds not previously described.
3. Activity mapping. Data from biological tests are linked back to specific molecules, helping identify which compound is responsible for an effect.
4. Optimization. Promising molecules are refined by chemists for potency, safety and oral absorption.

The Two Lead Areas, Explained

Atopic dermatitis

Often called eczema, atopic dermatitis is a chronic inflammatory skin condition that causes itching, dryness and rashes. Treatment ranges from moisturizers and topical medicines to injectable biologics and oral pills for more severe disease. Oral options with a favorable safety profile remain a goal for many developers.

Weight loss maintenance

Weight regain after reducing or stopping obesity medicines is a recognized challenge. A maintenance therapy aims to help people keep off weight they have already lost, potentially in a form that is easier to take long term than weekly injections. How such a therapy would fit into care is still being worked out by physicians and payers. Anyone considering treatment should consult their own doctor.

Understanding a Crossover Round

In a crossover round, the investor list usually changes character. Alongside venture firms, it includes mutual funds and other public-market investors that would expect to continue holding shares after an IPO. Companies value these investors because they can anchor demand in a future listing. Crossover investors, in turn, gain early access at a private-market price, accepting the risk that a listing may be delayed or never happen.

Questions Readers Ask

Does a crossover round mean an IPO is coming?

Often it precedes one, but not always. Companies can remain private if conditions are unfavorable or if private funding is sufficient.

What is a Phase 1 readout?

The release of results from a first-in-human study, focused primarily on safety, tolerability and dosing.

Why move several programs forward at once?

Running multiple programs in parallel spreads risk and can shorten timelines, but it requires the kind of capital a large round provides.

This article is for general information only and is not medical or investment advice.